<DOC>
	<DOCNO>NCT01785901</DOCNO>
	<brief_summary>This multi-centre , cross-sectional study plan conduct China . The study aim observe 1500 asthma patient already receive budesonide/formoterol combination treatment physician ' determination whose medication align package insert budesonide/formoterol approve China .</brief_summary>
	<brief_title>The Asthma Control Rate Achieved Budesonide/Formoterol Clinical Practice China</brief_title>
	<detailed_description>The asthma control rate achieve budesonide/formoterol clinical practice China .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Clinical diagnosis asthma least 6 month ; 2 . Prescribed budesonide/formoterol treatment least 3 month enrol ; 3 . Has use maintenance dose budesonide/formoterol least 4 week enrol . 1 . Participation clinical study within 3 month ; 2 . Have COPD history/suspicious COPD ; 3 . â‰¥ 10 pack year smoke history 4 . Used asthma maintenance medication accompany budesonide/formoterol within 3 month enrol 5 . With asthma exacerbation ( define asthma symptom deterioration result oral/rectal/parenteral GCS medication emergency room treatment hospitalisation ) within 4 week enrol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>control rate</keyword>
	<keyword>budesonide/formoterol</keyword>
	<keyword>Non-Interventional study</keyword>
</DOC>